Introduction to HPN-AS1 (G100128675)
Introduction to HPN-AS1
HPN-AS1 (Hepsin Pseudogene 1) is a long non-coding RNA (lncRNA) that has recently gained significant attention in the field of cancer research as a potential drug target and biomarker. This article aims to explore the various aspects of HPN-AS1, encompassing its structure, function, role in cancer, and the potential therapeutic implications it presents.
The Structure and Function of HPN-AS1:
HPN-AS1 is a lncRNA located on chromosome 19q13.2 and is transcribed from the antisense strand of the hepsin (HPN) gene. It is comprised of over 3000 nucleotides and lacks protein-coding potential. Despite being labeled as a pseudogene due to its inability to produce functional proteins, HPN-AS1 plays a critical role in various cellular processes.
Studies have shown that HPN-AS1 acts as a competing endogenous RNA (ceRNA), binding to microRNAs (miRNAs) and preventing their interaction with target messenger RNAs (mRNAs). This ceRNA mechanism allows HPN-AS1 to regulate the expression of numerous genes involved in cancer progression, such as those associated with cell cycle control, apoptosis, migration, and invasion.
HPN-AS1 as a Biomarker:
Several research studies have reported aberrant expression levels of HPN-AS1 in various cancer types, including hepatocellular carcinoma (HCC), colorectal cancer, gastric cancer, and lung cancer. The dysregulation of HPN-AS1 frequently correlates with tumor stage, metastasis, and overall patient survival, indicating its potential as a valuable biomarker for diagnostic and prognostic purposes.
In HCC, for instance, HPN-AS1 expression is significantly upregulated compared to healthy liver tissues. High levels of HPN-AS1 have been associated with advanced tumor stage, increased tumor size, and poor patient prognosis. Similarly, in lung cancer, elevated expression of HPN-AS1 is seen in both tumor tissues and plasma samples of patients with metastasis, highlighting its potential as a non-invasive biomarker for early cancer detection and monitoring treatment response.
The Role of HPN-AS1 in Cancer:
Emerging evidence suggests that HPN-AS1 plays a crucial role in cancer development and progression by regulating various molecular mechanisms. In hepatocellular carcinoma, HPN-AS1 promotes tumor growth and metastasis by inhibiting the tumor suppressor miR-203a-3p and activating the IL-11/STAT3 signaling pathway. Additionally, in gastric cancer, HPN-AS1 upregulation promotes the proliferation, migration, and invasion of cancer cells by acting as a sponge for miR-124-3p and enhancing the expression of its downstream target genes.
Furthermore, studies have demonstrated that HPN-AS1 governs epithelial-mesenchymal transition (EMT) in cancer cells, a critical process involved in metastasis. By sequestering miR-145-5p, HPN-AS1 enhances the expression of ZEB1, a transcription factor associated with EMT, thereby promoting cancer cell invasion and metastasis.
Therapeutic Implications and Conclusion:
The dysregulation of HPN-AS1 and its functional involvement in cancer progression highlight its potential as a therapeutic target for various types of cancer. By targeting HPN-AS1, researchers could potentially inhibit its ceRNA activity and restore the normal expression levels of tumor suppressor genes, thus suppressing cancer growth and metastasis.
Furthermore, the aberrant expression of HPN-AS1 makes it a promising biomarker for cancer diagnosis, prognosis, and treatment monitoring. Its presence in easily accessible biological samples, such as blood plasma, adds to its appeal as a non-invasive diagnostic tool that could facilitate early cancer detection and enable personalized treatment strategies.
In conclusion, HPN-AS1 is a fascinating lncRNA that holds immense potential as both a drug target and a biomarker in cancer research. Further investigations into its underlying molecular mechanisms and clinical utility are necessary to fully harness its therapeutic implications and enhance cancer management strategies.
Protein Name: HPN Antisense RNA 1
More Common Targets
A2M | A2MP1 | A4GALT | ABAT | ABCA1 | ABCB1 | ABCB6 | ABCC5 | ABCC9 | ABCF2 | ABCG2 | ABHD11-AS1 | ABHD3 | ABI1 | ABI2 | ACAA1 | ACACA | ACAN | ACE | ACE2 | ACE3P | ACOT8 | ACP5 | ACSF3 | ACTA2-AS1 | ACTBP12 | ACTG1P12 | ACTG1P22 | ACTL10 | ACTN1-DT | ACTR1A | ACTR1B | ACTR2 | ACTR3 | ACVR2B-AS1 | ADA | ADAD2 | ADAL | ADAM1B | ADAM22 | ADAM8 | ADAMTS15 | ADAMTS16 | ADAMTS17 | ADAMTS18 | ADAMTS19 | ADAMTS9-AS2 | ADAMTSL4 | ADCY4 | ADD1 | ADD2 | ADD3 | ADD3-AS1 | ADGRA3 | ADGRE2 | ADGRF3 | ADGRG2 | ADGRL1-AS1 | ADIPOQ-AS1 | ADM5 | ADPGK-AS1 | AEBP1 | AFF1-AS1 | AFG3L1P | AFM | AFP | AFTPH | AGA | AGAP1-IT1 | AGAP11 | AGAP2-AS1 | AGAP4 | AGER | AGL | AGO3 | AGO4 | AGRP | AGT | AGTR1 | AGTR2 | AGXT | AHCY | AHI1 | AHR | AIF1 | AK6P1 | AKAP9 | AKR1C1 | AKR1C2 | AKT1 | AKT3 | ALDH1L1-AS1 | ALG14 | ALK | ALKBH4 | ALMS1-IT1 | ALOX12-AS1 | ALOX15P1 | AMN1 | ANAPC16 | ANAPC1P1 | ANKFN1 | ANKIB1 | ANKRD16 | ANKRD20A12P | ANKRD20A13P | ANKRD20A17P | ANKRD22 | ANKRD24 | ANKRD26P3 | ANKRD49 | ANKRD61 | ANKRD63 | ANKRD66 | ANLN | ANO6 | ANTXR2 | ANTXRL | ANTXRLP1 | ANXA1 | ANXA11 | ANXA13 | ANXA2 | ANXA2P1 | ANXA2P2 | ANXA2P3 | ANXA3 | ANXA4 | ANXA5 | ANXA6 | ANXA7 | AOAH | AP1B1 | AP1G1 | AP1M2 | AP1S1 | AP2A2 | AP2B1 | AP2M1 | AP2S1 | AP3S1 | AP4B1-AS1 | APBB1IP | APCDD1L | APELA | APLNR | APOBEC3A_B | APOBEC3B-AS1 | APOBEC3H | APOC4-APOC2 | APOOP2 | APPAT | APTR | AR | ARAP1-AS2 | ARFRP1 | ARHGAP19-SLIT1 | ARHGAP22-IT1 | ARHGAP26-AS1 | ARHGAP26-IT1 | ARHGAP31-AS1 | ARHGEF26-AS1 | ARHGEF33 | ARHGEF38 | ARHGEF38-IT1 | ARHGEF7-AS1 | ARID2 | ARID3A | ARL14EP | ARL15 | ARL17B | ARL2-SNX15 | ARL4A | ARL4C | ARLNC1 | ARMCX4 | ARMCX5-GPRASP2 | ARMCX6 | ARPC1B | ARPC2 | ARPC3 | ARPC4 | ARPC4-TTLL3 | ARPC5 | ARPIN-AP3S2 | ARRDC3-AS1 | ARX | ASAP1-IT2 | ASNSD1 | ASPN | ASTN2-AS1 | ASXL1 | ATAD2B | ATE1-AS1 | ATF4P4 | ATM | ATN1 | ATP11A-AS1 | ATP13A5-AS1 | ATP2A1-AS1 | ATP5PBP5 | ATP5PO | ATP6AP1 | ATP6AP2 | ATP6V0A1 | ATP6V0B | ATP6V0CP1 | ATP6V0E1P1 | ATP6V1FNB | ATP6V1G2 | ATP6V1G2-DDX39B | ATP7A | ATP7B | ATP8B1-AS1 | ATP9A | ATR | ATRX | B3GALT9 | B3GNT6 | BAALC-AS1 | BABAM2-AS1 | BACE1-AS | BANCR | BAX | BBS12 | BCAP31 | BCAR3-AS1 | BCAS2P2 | BCAS3 | BCL11A | BCL2 | BCL2L1 | BCL2L10 | BCL2L11 | BCL2L2-PABPN1 | BCO1 | BCRP7 | BECN1 | BEST2 | BHLHA15 | BHLHE40-AS1 | BICRA | BIVM | BIVM-ERCC5 | BLACAT1 | BLOC1S1-RDH5 | BLOC1S5-TXNDC5 | BMPER | BMPR1B-DT | BMS1P17 | BMS1P21 | BMS1P7 | BNC2 | BOK-AS1 | BOLA3-DT | BORCS5 | BORCS6 | BORCS7 | BORCS7-ASMT | BPIFB5P | BRAF | BRCA1 | BRINP1 | BRWD1 | BSN-DT | BSPH1 | BSPRY | BTBD1 | BTBD16 | BTG4 | BTN2A3P | BTNL10P | BYSL | C10orf71 | C10orf71-AS1 | C10orf90 | C10orf95-AS1 | C11orf24 | C11orf71 | C11orf91 | C13orf46 | C16orf82 | C16orf95 | C17orf107 | C17orf99 | C18orf54 | C1orf68 | C1QBP | C1QL2 | C1QTNF1-AS1 | C1QTNF3-AMACR | C20orf181 | C21orf58 | C21orf62-AS1 | C21orf91 | C2CD4D | C2CD4D-AS1 | C4B_2 | C4orf46P3 | C5orf52